Download this infographic roadmap to understand how payers can impact a brand’s commercial journey.
On December 21, 2020, CMS published its final rule on how manufacturers are required to account for patient assistance programs in their best price calculations—doubling down on their initial rule despite industry pushback.
On November 20, HHS and the Trump Administration finalized two contentious rulings impacting Medicare Parts B and D. Both of these rulings come after a flurry of executive orders focused on combating rising drug costs in the US. Now, let’s take a closer look…
As one formulary decision-maker told us: “Recent regulation guidance on FDAMA114 frees up pharma to be more active in sharing HEOR information, and I think that helps…” To read this article in its entirety, please visit https://www.pm360online.com/learning-to-speak-heor/
A 2016 Harris Poll survey offered this shocking insight: The number of people who are uncomfortable with their ability to purchase healthcare is twice as high as… To read this article in its entirety, please visit https://www.pm360online.com/healthcares-financial-literacy-gap/
If payers are the fastest growing influencers in healthcare (and they are), why is it that payer-targeted advertising campaigns are often an afterthought? Pharma companies dedicate billions of dollars to… To read this article in its entirety, please visit http://www.pharmexec.com/are-pharma-marketers-fighting-last-war
Anyone who doesn’t feel the healthcare terrain shifting under our feet hasn’t been paying attention. One of the many factors currently rocking the marketplace is the introduction of the copay accumulator… To read this article in its entirety, please visit http://www.pharmexec.com/copay-showdown
The multiple forces dramatically reshaping the healthcare industry show no sign of abating. Influence continues to shift from providers to payers. Health plans are consolidating and new, unconventional players—from Amazon to Clover Health—are taking the field… To read this article in its entirety, please visit https://www.pm360online.com/seize-the-day/.
The Institute for Health Improvement (IHI) Triple Aim was created to establish and pursue three main objectives1: Improve the health of populations Improve the patient experience of care (including quality and satisfaction) Reduce the per capita cost of health care While these three objectives have been widely agreed upon, a fourth, less tangible priority has […]
Is pharma doing enough to maximize digital potential in payer marketing? A recent DRG Digital Manhattan Research study finds that pharmas’ marketing tactics have not evolved to meet the ever-changing data needs of today’s payer decision-makers, who now prefer to locate and receive targeted information online. Pharma companies have traditionally relied on face-to-face meetings between […]
Enlightened Pharma Companies Are Capitalizing on New Clarity from the FDA Regarding the Sharing of Information with Payers In the 1990’s, as healthcare costs spiraled out of control, the healthcare industry was inundated with cost-effectiveness analysis studies. While payers were hungry for this type of healthcare economic information (HCEI), regulations strictly limited what pharmaceutical companies […]
Pharmaceutical companies guaranteeing results and paying for failures? Payers paying more if a cancer patient has a shorter lifespan on a specific drug? Pharma guaranteeing the control of cholesterol? A few years ago, these seemed as unlikely as a biosimilar version of a blockbuster biologic. Now value-based contracting (VBC) seems to be the hottest topic […]
Biosimilars are knocking at our doors, and they certainly have a lot to say. Biosimilar products are biological products that are approved based on showing that they are highly similar to FDA-approved biological products, known as reference products, showing no clinically meaningful differences in terms of safety and effectiveness.
Some large payers with sophisticated infrastructure can answer their own questions – by analyzing their own data and assessing their broad “population situation” within and across multiple disease states. We have seen the big dogs start in areas known as the “low hanging fruit” – diabetes, CHF, COPD, etc., which are also areas where existing quality measures and/or incentives/disincentives are applied.